SQZ Biotechnologies Co: Nasdaq/NYSE listing notice — SQZ Biotech receives NYSE delisting notice; approves 1-for-10 reverse split

June 12, 2023, SQZ Biotechnologies Company (the “Company”) received written notice (the “NYSE Notification”) from the New York Stock Exchange (the “NYSE”) that the Company is not in compliance with Section 802.01B of the NYSE Listed Company Manual because the average global market capitalization of the Company over a consecutive 30 trading-day period and, at the same time, the Company’s last reported stockholders’ equity were each less than $50 million. The Company plans to notify the NYSE that it intends to submit a plan to cure the deficiency and to return to compliance with the NYSE continu

Item 1: To elect Howard Bernstein, M.D., Ph.D., Paul Bolno, M.D., and Marc Schegerin, M.D. as Class III directors to serve until the 2026 annual meeting of stockholders and until their respective successors shall have been duly elected and qualified. Class III Director Nominee For Withheld/Abstain Broker Non-Votes Howard Bernstein, M.D., Ph.D. 16,899,144 329,331 6,328,201 Paul Bolno, M.D. 15,368,658 1,859,817 6,328,201 Marc Schegerin, M.D. 16,908,459 320,016 6,328,201

Item 2: To approve amendments to the Company's restated certificate of incorporation, as amended, to effect a reverse stock split of the Company's common stock at a ratio ranging from any whole number between 1-for-10 and 1-for-20, as determined by the Board of Directors in its discretion, subject to the Board of Directors' authority to abandon such amendments. For Against Withheld/Abstain Broker Non-Votes 23,057,854 476,649 22,173 0

Item 3: To ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023. For Against Withheld/Abstain Broker Non-Votes 23,524,918 28,685 3,073 0